Optimizing cephalosporin treatments for children with multi-drug resistant tuberculosis.
Official title: PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TB
Funded at University of Texas Hlth Ctr at Tyler · NIH-10667456 · Data updated 2026-11-12
This study is looking at how to use certain antibiotics to help young children, especially those under two, who are fighting tough cases of tuberculosis that don't respond to standard treatments, so they can get better more safely and effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Ctr at Tyler NIH-funded |
| Lab location | 1 site (Tyler, United States) |
| Project start | September 1, 2019 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $306,226 |
| NIH project number | 5R01HD099756-05 |
| Project ID | NIH-10667456 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with multi-drug resistant tuberculosis, particularly those under the age of two.
✕Less likely to help
Patients who do not have multi-drug resistant tuberculosis or are older than two years may not benefit from this research.
What this research studies
This research focuses on developing effective treatment regimens using cephalosporin antibiotics for children suffering from multi-drug resistant tuberculosis (MDR-TB). The study aims to address the unique pharmacokinetic needs of pediatric patients, particularly those under two years old, who are at a higher risk of severe disease. By utilizing a hollow fiber system model, the researchers will evaluate the efficacy of various cephalosporins against drug-resistant strains of the tuberculosis bacterium. The goal is to repurpose existing antibiotics to create safer and more effective treatment options for young patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for children with MDR-TB, potentially reducing the severity and duration of their illness.
How similar studies have gone: While the use of cephalosporins for tuberculosis treatment is not widely tested, there is growing interest in repurposing existing antibiotics, suggesting potential for success in this novel approach.
Where this research is happening
-
University of Texas Hlth Ctr at Tyler
Tyler, United States Active
Researchers
- Principal investigator: Kant, Shashi — University of Texas Hlth Ctr at Tyler
- Study coordinator: Kant, Shashi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.